Alexza Pharmaceutica (ALXA) 1.0000 $ALXA Alexza

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexza Pharmaceutica (ALXA) 1.0000 $ALXA

Alexza Pharmaceuticals Acquired by Ferrer
PR Newswire - Tue Jun 21, 7:00AM CDT
Alexza Pharmaceuticals, Inc. (OTC: ALXA, "Alexza" and Grupo Ferrer Internacional, S.A. ("Ferrer" today announced the expiration of the tender offer (the "Offer" by Ferrer Pharma Inc., a wholly-owned indirect subsidiary of Ferrer ("Ferrer Pharma" , to purchase all of the outstanding shares of Alexza's common stock at a price (the "Offer Price" of $0.90 per share, net to the holder in cash (less any required withholding taxes and without interest), plus one contractual contingent value right (a "CVR" per share, which represents the right to receive a pro-rata share of up to four payment categories in an aggregate (i.e., to all CVR holders assuming all four payments are made) maximum amount of $32.8 million (after deduction of an estimated $2.2 million payment to Alexza's financial adviser for fees and expenses in connection with the transactions described herein and subject to further adjustment) if certain licensing payments and revenue milestones are achieved, net to the holder in cash (less any applicable withholding taxes and without interest).

INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
BusinessWire - Mon May 16, 9:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or the "Company" (Nasdaq: ALXA) relating to the proposed buyout of the Company by Ferrer Pharma, Inc.

ALEXZA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Ferrer Pharma, Inc. May be Unfair to Shareholders
BusinessWire - Mon May 16, 12:01PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" (NASDAQ: ALXA) concerning the acquisition by Ferrer Pharma, Inc. Under the terms of the agreement, Alexza shareholders will only receive $0.90 per Alexza share owned and a contingent value right entitling the stockholder to receive a pro-rata share of up to four payment categories in an aggregate maximum amount of $35 million if specified milestones are achieved. The consideration is significantly lower than at least one analyst's estimated value of $1.25.

SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Fri May 13, 10:15PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or the "Company" (Nasdaq: ALXA) relating to the proposed buyout of the Company by Ferrer Pharma, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Alexza Pharmaceuticals, Inc. to Ferrer Pharma, Inc. - ALXA
ACCESSWIRE - Fri May 13, 9:59AM CDT
NEW YORK, NY / ACCESSWIRE / May 13, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

Why is Alexza Pharmaceuticals (ALXA) Stock Soaring Today?
Madeleine Johnson - Zacks Investment Research - Tue May 10, 2:59PM CDT
On Tuesday, shares of pharmaceutical company Alexza Pharmaceuticals (ALXA) are soaring, up over 66% in afternoon trading after the company announced it has entered into a definitive agreement to be acquired by Spain-based Ferrer Pharma Inc.

Alexza to Cancel 2016 First Quarter Financial Results Earnings Call
PR Newswire - Tue May 10, 7:30AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company" today announced that it intends to issue a press release reporting financial results for the first quarter of fiscal 2016, as planned, immediately following the close of market on Wednesday, May 11, 2016. However, following the announcement on May 10, 2016, of Grupo Ferrer Internacional SA's proposed acquisition of Alexza, Alexza has elected not to conduct a conference call to discuss the quarterly financial results. The call was previously scheduled for May 11, 2016 at 5:00 p.m. Eastern Time.

Alexza to Report 2016 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 11, 2016
PR Newswire - Wed Apr 27, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company" will report results for its fiscal quarter ended March 31, 2016 on Wednesday, May 11, 2016, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time to provide a company update and discuss the financial results.

Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 12.02 (+0.26)

Alexza Reports Fourth Quarter and Year End 2015 Financial Results
PR Newswire - Mon Mar 28, 3:10PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company" today reported financial results for the quarter and year ended December 31, 2015. The net loss for the fourth quarter was $3.0 million compared to $6.7 million during the same quarter in 2014. The net loss for the years ended December 31, 2015 and 2014 was $21.3 million and $36.7 million, respectively. At December 31, 2015, Alexza had consolidated cash and cash equivalents of $7.8 million.

Alexza to Report 2015 Year End Financial Results and Provide Company Update on Monday, March 28, 2016
PR Newswire - Tue Mar 15, 4:00PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter and year ended December 31, 2015 on Monday, March 28, 2016 following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.

Alexza Pharmaceuticals Receives Positive Nasdaq Listing Determination
PR Newswire - Wed Mar 09, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza, or the "Company' announced today that on March 7, 2016 the Nasdaq Listing Qualifications Panel (the "Panel" issued a determination granting the Company's request for the continued listing of its common stock on The Nasdaq Capital Market ("Nasdaq" . The Company's continued listing on Nasdaq is subject to, among other things, the Company evidencing compliance with the minimum $35 million market value of listed securities requirement by June 14, 2016. In order to satisfy the market value of listed securities requirement, the Company must evidence a market capitalization of at least $35 million for a minimum of 10 consecutive business days on or before June 14, 2016. Alexza also remains subject to the 180-day period within which to evidence compliance with the minimum $1.00 bid price requirement, which does not expire until July 18, 2016. The Company is taking definitive steps to timely evidence compliance with the terms of the Panel's decision; however, there can be no assurance that it will be able to do so.

Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 254.68 (+1.73), AVXL: 3.65 (-0.19), ACOR: 25.39 (+0.11), BCLI: 2.54 (-0.01), FOLD: 6.67 (-0.05)

Global Insomnia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/65tkn8/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Insomnia Overview - Therapeutics Development - Pipeline Products for Insomnia - Overview - Pipeline Products for Insomnia - Comparative Analysis - Insomnia - Therapeutics under Development by Companies - Insomnia - Therapeutics under Investigation by Universities/Institutes - Insomnia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Insomnia - Products under Development by Companies - Insomnia - Products under Investigation by Universities/Institutes - Insomnia - Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evotec AG - Grupo Ferrer Internacional, S.A. - Heptares Therapeutics Limited - Intec Pharma ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Merck & Co., Inc. - Neurim Pharmaceuticals Ltd - Novartis AG - Reviva Pharmaceuticals Inc. - Rottapharm SpA - Shionogi & Co., Ltd. - Somnus Therapeutics, Inc. - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/65tkn8/insomnia
JNJ: 125.32 (+0.09), NTEC: 5.44 (+0.32), MRK: 58.73 (+0.07), ITCI: 40.87 (+0.07), NVS: 83.13 (-0.13)

New Strong Buy Stocks for December 31st
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
EARS: 4.18 (+0.17), ALLE: 72.26 (-0.13), AERI: 17.44 (+0.09), AVOL: 30.93 (-0.02)

New Strong Buy Stocks for December 29th
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AKAM: 50.38 (-0.15), ASNA: 8.06 (-0.07), AERI: 17.44 (+0.09), ARNA: 1.68 (+0.01)

Alexza Pharmaceuticals Announces Receipt of NASDAQ Staff Determination; Alexza to Request Hearing with NASDAQ Listing Qualifications Panel
PR Newswire - Tue Dec 22, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that on December 17, 2015, the Company received a letter from the Nasdaq Staff indicating that the Company had not regained compliance with the $35 million market capitalization requirement for continued listing on The Nasdaq Capital Market by the end of the previously granted compliance period, which expired on December 16, 2015. As a result, the Company would be subject to delisting unless it timely requests a hearing before a Nasdaq Listing Qualifications Panel (the "Panel" . Based on the foregoing, the Company intends to timely request a hearing before the Panel at which it will present its plan of compliance and request a further extension of time. The Panel has the discretion to grant the Company up to an additional 180 calendar days from December 17, 2015 to regain compliance. This request will automatically stay any delisting or suspension action pending the issuance of a final decision by the Panel and the expiration of any further extension granted by the Panel. There can be no assurance that the Panel will ultimately grant an extension of the compliance period.

4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Tue Dec 22, 10:51AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch that have been attracting the attention of investors.
ARGS: 5.28 (+0.02), PSDV: 3.92 (+0.10), SRNE: 6.42 (+0.13)

Alexza Pharmaceuticals Announces Interim Results from its Phase 2a Study of AZ-002 (Staccato® alprazolam) in Epilepsy Patients
PR Newswire - Mon Dec 21, 3:10PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced interim results of its Phase 2a study of AZ-002 (Staccato® alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study. AZ-002 is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 19

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 13

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 11

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 6

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 5

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 12

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Clinch Scores Big with Two Prestigious Industry Honors

Updated Category News Views 14

Clinch's Dual Triumph in Advertising Innovation No one throws a ticker symbol over their cereal for recognizing brilliance, but when an outfit like Clinch gets double applause at the big dance, even we old-timers have to tip our hats. On November 16, 2026, the advertising world saw some fireworks. Clinch took home not one but two hefty awards—the kind that say you've...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 28

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 64

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 40 Years: The Evolution of Fudan SoM

Updated Category News Views 275

Fudan SoM Celebrates a Milestone in Business Education The Fudan University School of Management recently celebrated its 40th anniversary with great enthusiasm, showcasing a commitment to fostering global business education. This significant event coincided with the launch of the 2025 Global Business Education Deans' Forum and Expo, a pivotal gathering that highlights...

Continue Reading
ICU Medical Stock Hits Record Low: What Investors Should Know

Updated Category News Views 321

ICU Medical Faces Significant Market Challenges Amidst a turbulent market landscape, ICU Medical (NASDAQ: ICUI) has witnessed its stock price decline to a 52-week low of $1.69, resulting in a market capitalization plummeting to approximately $7.65 million. The company’s substantial dip in value, which is around -86.22% over the past year, highlights a significant...

Continue Reading
Sagimet Biosciences Unveils Comprehensive Financial Results and Milestones

Updated Category News Views 178

Sagimet Biosciences Shares 2024 Financial Highlights Sagimet Biosciences Inc. (NASDAQ: SGMT), a prominent clinical-stage biopharmaceutical firm focusing on innovative therapies for metabolic and fibrotic disorders, recently revealed its financial outcomes for the full year ended December 31, 2024. With notable advancements in their drug pipeline, Sagimet is...

Continue Reading
Exploring the Expanding Opportunities in Cannabidiol Market

Updated Category News Views 158

Cannabidiol Market Growth Projections The global cannabidiol (CBD) market is a rapidly evolving sector that is transforming the healthcare landscape. With increasing recognition of its therapeutic potential, the market was valued at approximately USD 8.97 billion in 2024 and is set to reach an impressive USD 38.97 billion by 2034. This remarkable growth, projected at a...

Continue Reading
Kelley Morris Appointed President of Hospital Foundations

Updated Category News Views 476

Kelley Morris Steps into Leadership Role The Memorial and Joe DiMaggio Children's Hospital Foundations have made a significant change in leadership by appointing Kelley Morris, MHA, as President and CEO. With an impressive background spanning over 25 years in healthcare philanthropy, operations, and research administration, Morris is set to lead the Foundations in...

Continue Reading